http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 10:29:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+06++Filed+by%3A+Forbes+William+P/26615666.html si-local-file:///var/storage/secattach/20260608/26615666.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+06++Filed+by%3A+Forbes+William+P/26615666.html Mon, 08 Jun 2026 10:29:00 -0400 HRTX O.00063315 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+06++Filed+by%3A+Forbes+William+P/26615666.html si-local-file:///var/storage/secattach/20260608/26615666.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+06++Filed+by%3A+Forbes+William+P/26615666.html Mon, 08 Jun 2026 10:29:00 -0400 HRTX O.00063315 http://www.streetinsider.com/Analyst+PT+Change/Heron+Therapeutics+%28HRTX%29+PT+Lowered+to+%242+at+H.C.+Wainwright/26594985.html H.C. Wainwright analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $2.00 (from $4.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Heron+Therapeutics+%28HRTX%29+PT+Lowered+to+%242+at+H.C.+Wainwright/26594985.html Wed, 03 Jun 2026 06:22:31 -0400 HRTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+02/26593197.html si-local-file:///var/storage/secattach/20260602/26593197.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+02/26593197.html Tue, 02 Jun 2026 17:15:00 -0400 HRTX O.00063315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+02/26593197.html si-local-file:///var/storage/secattach/20260602/26593197.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Jun+02/26593197.html Tue, 02 Jun 2026 17:15:00 -0400 HRTX O.00063315 http://www.streetinsider.com/Downgrades/Needham+Downgrades+Heron+Therapeutics+%28HRTX%29+to+Hold/26591368.html <p>Needham analyst Serge Belanger downgraded Heron Therapeutics (NASDAQ: HRTX) from Buy to Hold.</p><p>For an analyst ratings summary and ratings history on Heron Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=HRTX">click here</a>. For more ratings news on Heron Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=HRTX&amp;type=analyst">click here</a>.</p><p>Shares of Heron Therapeutics closed at $0.83 yesterday.</p> http://www.streetinsider.com/Downgrades/Needham+Downgrades+Heron+Therapeutics+%28HRTX%29+to+Hold/26591368.html Tue, 02 Jun 2026 16:00:26 -0400 HRTX http://www.streetinsider.com/Litigation/Heron+Therapeutics+loses+patent+case+for+CINVANTI+drug/26587941.html <p>Heron Therapeutics, Inc. (NASDAQ: HRTX) announced that the U.S. District Court for the District of Delaware ruled against the company in patent litigation with Azurity Pharmaceuticals regarding CINVANTI (aprepitant) injectable emulsion. The court held that claims in Heron's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.</p><p>The decision does not affect any existing settlement agreements related to CINVANTI or APONVIE (aprepitant) injectable emulsion. Heron plans to appeal the ruling to the United States Court of Appeals for the Federal Circuit.</p><p>"We are disappointed with this initial result of the litigation and will vigorously pursue our appeal and all available remedies, including equitable http://www.streetinsider.com/Litigation/Heron+Therapeutics+loses+patent+case+for+CINVANTI+drug/26587941.html Tue, 02 Jun 2026 08:12:51 -0400 HRTX http://www.streetinsider.com/Corporate+News/Heron+Therapeutics+loses+patent+case+for+CINVANTI+drug/26587941.html <p>Heron Therapeutics, Inc. (NASDAQ: HRTX) announced that the U.S. District Court for the District of Delaware ruled against the company in patent litigation with Azurity Pharmaceuticals regarding CINVANTI (aprepitant) injectable emulsion. The court held that claims in Heron's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.</p><p>The decision does not affect any existing settlement agreements related to CINVANTI or APONVIE (aprepitant) injectable emulsion. Heron plans to appeal the ruling to the United States Court of Appeals for the Federal Circuit.</p><p>"We are disappointed with this initial result of the litigation and will vigorously pursue our appeal and all available remedies, including equitable http://www.streetinsider.com/Corporate+News/Heron+Therapeutics+loses+patent+case+for+CINVANTI+drug/26587941.html Tue, 02 Jun 2026 08:12:51 -0400 HRTX http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Press+Releases/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html <p align="justify">CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable http://www.streetinsider.com/Globe+Newswire/U.S.+District+Court+Issues+Decision+Regarding+CINVANTI%C2%AE+Patents/26587940.html Tue, 02 Jun 2026 08:12:00 -0400 A.04758039 HRTX O.00063315 O.47642696 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++HERON+THERAPEUTICS%2C+INC.+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26482911.html si-local-file:///var/storage/secattach/20260513/26482911.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++HERON+THERAPEUTICS%2C+INC.+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26482911.html Wed, 13 May 2026 09:06:00 -0400 HRTX O.00063315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++HERON+THERAPEUTICS%2C+INC.+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26482911.html si-local-file:///var/storage/secattach/20260513/26482911.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++HERON+THERAPEUTICS%2C+INC.+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26482911.html Wed, 13 May 2026 09:06:00 -0400 HRTX O.00063315 http://www.streetinsider.com/Analyst+PT+Change/Heron+Therapeutics+%28HRTX%29+PT+Lowered+to+%244+at+H.C.+Wainwright/26472596.html (Updated - May 12, 2026 6:55 AM EDT) <p>H.C. Wainwright analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $4.00 (from $6.00) while maintaining a Buy rating.</p><p>The analyst commented: "We anticipated a weaker than forecast quarter for HRTX, given the pressure on elective surgeries from the weather disruptions in early January as well as reimbursement reverifications and deductible resets which occur in 1Q26. We recently revised our numbers down ahead of 1Q26 earnings; however, HRTX reported results were below our revised $35.5M revenue estimate, with 1Q26 revenue of $34.7M, also below FactSet consensus of $36.7M. We view http://www.streetinsider.com/Analyst+PT+Change/Heron+Therapeutics+%28HRTX%29+PT+Lowered+to+%244+at+H.C.+Wainwright/26472596.html Tue, 12 May 2026 06:55:11 -0400 HRTX http://www.streetinsider.com/Analyst+Comments/Heron+Therapeutics+%28HRTX%29+PT+Lowered+to+%244+at+H.C.+Wainwright/26472596.html (Updated - May 12, 2026 6:55 AM EDT) <p>H.C. Wainwright analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $4.00 (from $6.00) while maintaining a Buy rating.</p><p>The analyst commented: "We anticipated a weaker than forecast quarter for HRTX, given the pressure on elective surgeries from the weather disruptions in early January as well as reimbursement reverifications and deductible resets which occur in 1Q26. We recently revised our numbers down ahead of 1Q26 earnings; however, HRTX reported results were below our revised $35.5M revenue estimate, with 1Q26 revenue of $34.7M, also below FactSet consensus of $36.7M. We view http://www.streetinsider.com/Analyst+Comments/Heron+Therapeutics+%28HRTX%29+PT+Lowered+to+%244+at+H.C.+Wainwright/26472596.html Tue, 12 May 2026 06:55:11 -0400 HRTX http://www.streetinsider.com/Earnings/Heron+Therapeutics+%28HRTX%29+Misses+Q1+EPS+by+2c+%3B+Offers+Guidance/26465516.html <p>Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $34.7 million versus the consensus estimate of $39.28 million.</p><p><strong>GUIDANCE:</strong></p><p>Heron Therapeutics sees FY2026 revenue of $173-183 million, versus the consensus of $174.7 million.</p><p>For earnings history and earnings-related data on Heron Therapeutics (HRTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=HRTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Heron+Therapeutics+%28HRTX%29+Misses+Q1+EPS+by+2c+%3B+Offers+Guidance/26465516.html Mon, 11 May 2026 08:06:57 -0400 HRTX http://www.streetinsider.com/Guidance/Heron+Therapeutics+%28HRTX%29+Misses+Q1+EPS+by+2c+%3B+Offers+Guidance/26465516.html <p>Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $34.7 million versus the consensus estimate of $39.28 million.</p><p><strong>GUIDANCE:</strong></p><p>Heron Therapeutics sees FY2026 revenue of $173-183 million, versus the consensus of $174.7 million.</p><p>For earnings history and earnings-related data on Heron Therapeutics (HRTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=HRTX">click here</a>.</p> http://www.streetinsider.com/Guidance/Heron+Therapeutics+%28HRTX%29+Misses+Q1+EPS+by+2c+%3B+Offers+Guidance/26465516.html Mon, 11 May 2026 08:06:57 -0400 HRTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Mar+31/26465421.html si-local-file:///var/storage/secattach/20260511/26465421.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Mar+31/26465421.html Mon, 11 May 2026 08:01:00 -0400 HRTX O.00063315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Mar+31/26465421.html si-local-file:///var/storage/secattach/20260511/26465421.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HERON+THERAPEUTICS%2C+INC.++For%3A+Mar+31/26465421.html Mon, 11 May 2026 08:01:00 -0400 HRTX O.00063315 http://www.streetinsider.com/Press+Releases/Heron+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Reaffirms+Guidance/26465377.html <ul><li><em>Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF</em><em>®</em><em> (+27%) and APONVIE</em><em>®</em><em> (+50%)</em></li><li><em>Q1 2026 total net revenue of $34.7 million</em></li><li><em>Reached settlement with Baxter Healthcare Corporation in CINVANTI</em><em>®</em><em> patent litigation</em></li><li><em>Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million Adjusted EBITDA</em></li></ul> <p align="justify">CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.</p> <p align="justify">“Despite typical first-quarter seasonality and unusual weather-related disruption early http://www.streetinsider.com/Press+Releases/Heron+Therapeutics+Announces+First+Quarter+2026+Financial+Results+and+Reaffirms+Guidance/26465377.html Mon, 11 May 2026 08:00:00 -0400 A.17935361 A.50204454 A.50208796 HRTX O.00063315 O.00074332 O.11226248 O.16894485